Anyone managing central diabetes insipidus or a child's persistent bedwetting has likely come across desmopressin as a treatment option. Understanding what it treats, what evidence supports it, and what side effects have been reported can help frame a conversation with a prescriber.
Key takeaways
- Desmopressin acetate is approved for central diabetes insipidus and for temporary polyuria and polydipsia after head trauma or pituitary surgery.
- It is also approved for managing primary nocturnal enuresis (bedwetting).
- Desmopressin does not work for nephrogenic diabetes insipidus.
- More than 150 trials have studied desmopressin across multiple conditions.
- The most reported adverse event in safety databases is hyponatraemia, a low blood sodium level.
What Desmopressin Is
Desmopressin acetate is marketed under that same name as its brand designation. It functions as antidiuretic replacement therapy, meaning it helps the body retain water when natural antidiuretic hormone activity is insufficient or needs support.
What Desmopressin Is Approved For
Desmopressin acetate tablets are indicated as antidiuretic replacement therapy for central diabetes insipidus. They are also approved for the temporary polyuria and polydipsia that can follow head trauma or surgery in the pituitary region. Diagnosis for these uses is typically confirmed through tests such as water deprivation testing, hypertonic saline infusion testing, or response to antidiuretic hormone, and ongoing response can be tracked with urine volume and osmolality measurements. Separately, desmopressin acetate tablets are approved for managing primary nocturnal enuresis. The label specifically notes that desmopressin acetate is not effective for nephrogenic diabetes insipidus. No boxed warning is present on the label.
What the Evidence Shows
Desmopressin has been studied in more than 150 registered clinical trials spanning conditions well beyond its core approved uses. One completed phase 4 trial compared exercise to desmopressin (DDAVP) in patients with mild hemophilia A. Another completed trial evaluated an orally disintegrating desmopressin tablet against standard tablets for primary nocturnal enuresis. A phase 3 trial looking at desmopressin for nocturia in obstructive sleep apnea patients was terminated.
Reported Side Effects
Safety reports submitted to FAERS represent counts of reported events, not confirmed incidence or proven causation. The most frequently reported reaction is hyponatraemia, with 357 reports, reflecting desmopressin's known effect on water retention and sodium balance. Headache (268 reports) and dizziness (138 reports) are also commonly reported. Gastrointestinal reactions include nausea (204 reports) and vomiting (155 reports), alongside general fatigue (172 reports). Reports of drug ineffectiveness (258) and off label use (146) were also noted in the data.